Trends in utilization of microaxial flow pump and intra-aortic balloon pump across 3 countries
Ko DT, Ayayo S, Banerjee A, Fu C, Haldenby O, Mamas MA, Mohamed MO, Qiu F, Cram P, Landon BE. JAMA Intern Med. 2025; e253881. Epub 2025 Aug 11.
Aims — To determine what proportion of patients with heart failure are eligible for cardiac resynchronization therapy (CRT).
Methods and Results — Eligibility criteria from the trials establishing the efficacy of CRT were applied to two prospective cohorts: the first enrolled patients with newly diagnosed heart failure discharged from 103 hospitals between April 1999 and March 2001 (‘the hospital discharge cohort’); the second enrolled patients seen in a specialized clinic between August 2003 and January 2004 (‘the specialty clinic cohort’). In the hospital discharge cohort, 73 patients (3% of the 2640 patients with ischaemic or dilated cardiomyopathy and 1% of all 9096 patients with heart failure discharged alive) met trial eligibility criteria: LVEF≤0.35, QRS ≥120 ms, sinus rhythm, and NYHA class III or IV symptoms despite the treatment with ACE-inhibitor/angiotensin receptor blocker and beta-blocker. In the specialty clinic cohort, 54 patients (21% of the 263 patients with ischaemic or dilated cardiomyopathy and 17% of all 309 patients with heart failure) met these criteria. If persistent symptoms despite taking spironolactone were required for CRT eligibility, then the proportions qualifying dropped to 1% in the hospital discharge cohort and 18% in the specialty clinic cohort.
Conclusion — Few heart failure patients meet trial eligibily criteria for CRT.
McAlister FA, Tu JV, Newman A, Lee DS, Kimber S, Cujec B, Armstrong PW. Eur Heart J. 2006; 27(3):323-9. Epub 2005 Aug 16.
The ICES website uses cookies. If that’s okay with you, keep on browsing, or learn more about our Privacy Policy.